Faraone Stephen V, Wigal Sharon B, Hodgkins Paul
State University of New York Upstate Medical University, NY, USA.
J Atten Disord. 2007 Jul;11(1):74-82. doi: 10.1177/1087054706292196.
Compare observed and forecasted efficacy of mixed amphetamine salts extended release (MAS-XR; Adderall) with atomoxetine (Strattera) in ADHD children.
The authors analyze data from a randomized, double-blind, multicenter, parallel-group, forced-dose-escalation laboratory school study of children ages 6 to 12 with ADHD combined or hyperactive/impulsive type. Primary efficacy measures are attention and deportment scores on the SKAMP behavioral rating scale, and secondary efficacy measures are academic performance scores from the PERMP test.
MAS-XR elicits greater improvements than atomoxetine in each domain within 3 weeks of treatment, including attention, number of math problems attempted and correct, and overall clinical functioning. Treatment differences in each outcome measure at subsequent weeks are projected from generalized estimating equations to become greater with the duration of extension of the treatment regimen.
This study suggests that relative advantages of MAS-XR seen in the first 3 weeks are likely to be maintained in subsequent weeks.
比较缓释混合苯丙胺盐（MAS-XR；阿得拉）与托莫西汀（择思达）对多动症儿童的观察疗效和预测疗效。
作者分析了一项针对6至12岁多动症合并型或多动/冲动型儿童的随机、双盲、多中心、平行组、强制剂量递增实验室学校研究的数据。主要疗效指标是SKAMP行为评定量表上的注意力和行为评分，次要疗效指标是PERMP测试中的学业成绩评分。
在治疗的3周内，MAS-XR在各个领域（包括注意力、尝试和正确解答的数学问题数量以及整体临床功能）比托莫西汀引起更大的改善。后续几周各结局指标的治疗差异通过广义估计方程预测，随着治疗方案延长持续时间而变得更大。
本研究表明，MAS-XR在前3周出现的相对优势可能在后续几周得以维持。
Zotero 插件